BridgeBio Pharma (BBIO) Cash from Financing Activities (2018 - 2026)

BridgeBio Pharma has reported Cash from Financing Activities for 9 years, with the latest figure at $549.9 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 811.5% year-over-year to $549.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $848.9 million (up 60.39% YoY) and the FY2025 annual result came in at $359.3 million, down 52.0% from the prior year.
• Cash from Financing Activities improved to $549.9 million in Q1 2026 per BBIO's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $549.9 million in Q1 2026 and troughed at -$20.8 million in Q2 2022.
• A 5-year average of $123.3 million and a median of $1.4 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 1395.04% in 2022, then jumped 94005.62% in 2023.
• Over 5 years, Cash from Financing Activities stood at $6.4 million in 2022, then tumbled by 170.93% to -$4.5 million in 2023, then jumped by 10578.24% to $473.9 million in 2024, then slumped by 100.46% to -$2.2 million in 2025, then surged by 25301.28% to $549.9 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $549.9 million, -$2.2 million, and -$894000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.